Today: 9 June 2026
BHP stock rises as it stays out of the Rio-Glencore chase — what investors watch next
13 January 2026
1 min read

BHP stock rises as it stays out of the Rio-Glencore chase — what investors watch next

New York, Jan 13, 2026, 00:52 EST — Market closed

BHP Group’s U.S.-listed shares climbed 1.7% to $62.80 on Monday as investors digested reports that the miner isn’t planning a rival bid for Glencore. Instead, BHP appears set to wait on Rio Tinto’s takeover discussions, according to two sources familiar with the situation. Those sources also said BHP doesn’t see Glencore’s coal and trading units as a good strategic fit. BHP declined to comment.

The stance matters now because it removes one potential spoiler, at least for the time being, amid ongoing mining deal talks focused largely on copper. Copper, essential for power cables and grid equipment, has seen demand forecasts driven by data centers and electrification efforts, pushing miners to search for more supply.

It also raises the stakes on BHP’s next move with its growth strategy — whether to invest, acquire, or hold back — as investors remain quick to slam pricey mergers and acquisitions, especially those mistimed in the cycle.

Rio Tinto’s U.S.-listed shares gained 2.1%, closing at $82.88. Copper-focused miners in New York saw similar gains, with Freeport-McMoRan jumping 3.8%. For now, BHP’s stock is behaving more like a metals play than a potential takeover target.

Still, some in the market argue BHP can’t avoid the consolidation trend much longer. “This is yet another example that the mining space is consolidating,” Mark Kelly, CEO of advisory firm MKI Global, noted, saying major players face growing pressure to take corporate action. Richard Hatch at Berenberg labeled BHP “the most likely interloper” in a potential Rio-Glencore tie-up. Meanwhile, RBC’s Kaan Peker pointed out BHP’s copper growth outlook is “cleaner” than that of a merged rival, suggesting a move might not be necessary. George Cheveley from Ninety One added any bid could prove “difficult emotionally” after BHP’s failed Anglo American attempt. Reuters reported Rio has until Feb. 5 to make a formal offer under UK takeover rules. Reuters

Setting aside the deal chatter, a recent filing revealed BHP granted 3,963,655 unquoted performance rights dated Dec. 31 under its long-term incentive scheme, a routine disclosure linked to employee equity grants. That filing also listed BHP’s total ordinary shares outstanding at 5,078,913,175.

The copper crunch at the heart of the discussion persists. Chile’s Codelco, the largest copper miner globally, projects 2026 production at 1.344 million metric tons. Still, it warned that declining ore grades and project delays continue to hamper supply expansion.

The risk here is that the deal story becomes nothing more than a mirage: negotiations could collapse, regulators might insist on asset sell-offs, and commodity prices can shift quicker than bankers anticipate. When copper tumbles, interest in large, complicated mergers tends to fade right along with it.

Investors are focused on BHP’s operational review set for Jan. 20, followed by its half-year earnings on Feb. 17. Changes in capital allocation, copper strategy, or cost outlook usually surface swiftly in the stock around these dates.

Stock Market Today

  • S&P 500 Rallies on Chipmaker Gains; Crude Oil Prices Retreat After Iran-Israel Ceasefire Signal
    June 9, 2026, 9:24 AM EDT. The S&P 500 gained +0.30% on Monday, driven by renewed investor interest in artificial intelligence boosting chipmakers. Nasdaq 100 rose +1.58%, while the Dow slipped -0.16%, dragged lower by Apple's -1% drop amid lukewarm AI platform feedback. Crude oil prices surged over +4% initially due to Iran-Israel tensions but retreated after Iran signaled an end to its current military operation. The market discounts a low 3% chance of a +25 basis point rate hike by the Federal Reserve on June 16-17. Treasury yields climbed, with 10-year notes reaching a two-week high of 4.58%, pressured by strong US jobs data and heavy upcoming Treasury auctions. Overseas markets closed mixed, with China's Shanghai Composite down -1.70% and Japan's Nikkei falling -3.85%.

Latest articles

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

9 June 2026
Factorial Energy surged 16% to $13.80 in its Nasdaq debut as FAC, with premarket trading near $20.70, after replacing CGCT via SPAC merger that raised over $100 million for battery commercialization and implied a $1.3 billion equity value; former CGCT shares now trade as FAC, with founders retaining majority voting power and staged lock-up releases ahead.
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

9 June 2026
Pfizer shares fell 1.7% premarket to $25.62 as investors weighed an FDA label expansion for hemophilia drug Hympavzi—now the first subcutaneous non-factor therapy for children 6-11 with hemophilia B—against slower progress in obesity drugs, with mid-stage data for weight-loss shot berobenatide showing a 23.3% vomiting rate and no immediate growth catalyst for the $147 billion company.
Tesla stock edges up after hours as robotaxi deadlines, CPI and earnings line up as next tests for TSLA
Previous Story

Tesla stock edges up after hours as robotaxi deadlines, CPI and earnings line up as next tests for TSLA

Locked out of $22B: Canadian real estate funds freeze withdrawals as gates spread
Next Story

Locked out of $22B: Canadian real estate funds freeze withdrawals as gates spread

Go toTop